News

Here's some of what is coming soon to NeurologyLive® this week.

Xenos Mason, MD, a neurologist specializing in movement disorders, provides commentary on an early-stage study evaluating induced pluripotent stem cells for patients with Parkinson disease.

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Dravet syndrome treatment paradigm!

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

PTC Therapeutics pulls ataluren’s US NDA for nonsense-mutation Duchenne after FDA doubts efficacy, despite trial and registry signals of benefit.

Neurology News Network for the week ending February 21, 2026. [WATCH TIME: 5 minutes]

Experts shared their clinical perspectives on trending topics at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held February 5-7, 2026.

An associate professor in neurosurgery at Duke University discussed his presentation on novel meningeal immune interactions and interferon signaling in multiple sclerosis at the ACTRIMS Forum 2026. [WATCH TIME: 3 minutes]

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jeff Chamberlain, PhD. [LISTEN TIME: 23 minutes]

Phase 2 trials suggest LT3001 is safe in acute ischemic stroke and may boost day-90 recovery, paving the way for a global Phase 3.

The FDA granted premarket approval to Balt Inc.’s Squid liquid embolic agent for middle meningeal artery embolization, offering a minimally invasive option to reduce treatment failure in patients with large symptomatic chronic subdural hematomas.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

Leaders from Brainomix provided commentary on data from ISC 2026, discussing how automated net water uptake from routine CT imaging may refine stroke severity assessment, thrombectomy selection, and system-level treatment equity.

The chief medical advisor at the Muscular Dystrophy Association also discussed what he personally is looking forward to at the conference this year. [WATCH TIME: 4 minutes]

52-week trial data shows inebilizumab sustains gains in generalized myasthenia gravis, cuts prednisone, and spotlights CD

A pediatric neurologist at the UCL Institute of Neurology in London, England discussed how pediatric-onset MS is marked by intense inflammation, unique neurodevelopmental considerations, and evolving treatment paradigms at ACTRIMS 2026. [WATCH TIME: 5 minutes]

High-dose constraint-induced therapy boosts arm function in toddlers after perinatal stroke, with gains lasting 6 months in phase 3 trial.

The professor of neurology at Cleveland Clinic gave insights on hematopoietic stem cell transplantation, CAR T-cell strategies, and the ongoing challenges of developing immune reconstitution and repair therapies in multiple sclerosis.

The FDA expands pitolisant, marketed as Wakix, to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making pitolisant the only nonscheduled option for excessive daytime sleepiness and cataplexy attacks.

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

Andrew Russman, DO, director of Cleveland Clinic’s Comprehensive Stroke Center, provided an analysis of the phase 3 OCEANIC-STROKE data of asundexian in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack.

A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how AI-powered caregiver training platforms like YayaGuide can personalize dementia care education for family caregivers.

The director of the clinical neuroimmunology fellowship at Cleveland Clinic discussed the evolving clinical trial landscape of hematopoietic stem cell transplantation and other cell-based therapies in multiple sclerosis. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.